A Trial of Isoniazid for the Reversion of Interferon Gamma ELISPOT in Tuberculosis (TB) Case Contacts

Condition(s) targeted: Tuberculosis

Intervention: Isoniazid (Drug); Isoniazid (Drug); Placebo of Isoniazid tablets 300mg (Drug)

Phase: N/A

Status: Recruiting

Sponsored by: Medical Research Council Laboratories, Gambia

Official(s) and/or principal investigator(s):
Philip C Hill, MPH FRACP, Principal Investigator, Affiliation: MRC Laboratories, Gambia
Roger H Brookes, PhD, Principal Investigator, Affiliation: MRC laboratories, Gambia
Richard A Adegbola, PhD FRCPath, Study Chair, Affiliation: MRC laboratories, Gambia

Overall contact:
Philip C Hill, MPH, FRACP, Phone: +220 4495442-5, Ext: 491, Email: phill@mrc.gm

There are new TB vaccines already developed that need to be tried in humans to assess their efficacy.

The researchers had previously shown that production of interferon gamma by T cells in response to TB antigens is a more specific marker of TB infection.

The researchers hypothesize that this can be used as a reliable early marker of TB vaccine efficacy. The researchers expect to show a significantly increased reversion of this test in household contacts of TB patients given Isoniazid prophylaxis treatment for 6 months.

Official title: A Double Blind Placebo-Controlled Randomized Trial of Isoniazid for the Reversion of a Positive IFNg ELISPOT in TB Case Contacts

Study design: Treatment, Randomized, Double Blind (Subject, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Efficacy Study

Primary outcome:

Qualitative IFN-g ELISPOT reversion

Quantitative IFN-g ELISPOT reversion

Detailed description: Current efforts to control the spread of tuberculosis are failing. An increasingly large number of new generation vaccines are being produced and a plan for assessing their ability to prevent disease and treat infection needs to be developed.

The MRC Labs in The Gambia is well positioned to conduct safety and immunogenicity studies and also to conduct trials of the therapeutic effect of these vaccines in preventing disease in case contacts who are infected.

This study is part one of a three-step plan to develop a reliable early surrogate marker of the therapeutic efficacy of new TB vaccines.

The three-step plan is as follows:

- Evaluate the ability of isoniazid, known to be effective in the treatment of MTB

infection, to revert the antigen-specific IFNg-ELISPOT in ESAT-6 and/or CFP-10 positive contacts of TB patients.

- Compare the ability of different combinations of a TB vaccine and isoniazid to revert

the ELISPOT in a 4-arm randomised trial using: 1) isoniazid alone, 2) a TB vaccine alone, 3) a combination of isoniazid and TB vaccine, and 4) placebo

- Compare, in a randomized trial, the ability of TB vaccine or vaccine plus isoniazid

versus isoniazid alone to prevent the development of secondary disease.

For this first step the researchers will test the following hypothesis:

- Those receiving isoniazid have a significantly higher reversion rate of MTB-specific

responses as measured with IFNg-ELISPOT assays compared to those who receive a placebo.

Minimum age: 15 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Healthy person aged 15 years and above

- Normal medical history and physical examination

- Normal biochemistry and haematological indices

- Mantoux ≥ 10mm

- Negative HIV antibody test

- No serological evidence of hepatitis B virus (HBV) infection

- Normal Chest X-ray

- ESAT6 and/or CFP-10 peptides and ESAT6/CFP-10 protein positive (≥10 SFC for ESAT 6 or

CFP-10 and ESAT6/CFP-10 protein).

- Index case is sputum smear positive

- Index case has chest X ray (CXR) characteristics of TB

Exclusion Criteria:

- Pregnant female

- Haemoglobin <8 g/dl

- Previous history of tuberculosis

- Clinical case of tuberculosis

- Current participation in another clinical trial, or within 12 weeks of this study.

- Any other factor that might increase the risk of an adverse outcome from

participation in the trial

- Significant history or evidence of skin disorder, allergy, immunodeficiency, organ

specific disorders causing significant immunodeficiency.

Philip C Hill, MPH, FRACP, Phone: +220 4495442-5, Ext: 491, Email: phill@mrc.gm

MRC Laboratories, Banjul, KSMD Po Box 273 Banjul, Gambia; Recruiting
Ifedayo MO Adetifa, MB;BS, FWACP, Phone: +4495442-5, Ext: 441, Email: iadetifa@mrc.gm
Philip C Hill, MPH, FRACP, Phone: +4495442-5, Ext: 491, Email: phill@mrc.gm
Philip C Hill, MPH FRACP, Principal Investigator
Roger H Brookes, Ph.D, Principal Investigator

MRC laboratories, Gambia website

Related publications:

Hill PC, Brookes RH, Fox A, Fielding K, Jeffries DJ, Jackson-Sillah D, Lugos MD, Owiafe PK, Donkor SA, Hammond AS, Otu JK, Corrah T, Adegbola RA, McAdam KP. Large-scale evaluation of enzyme-linked immunospot assay and skin test for diagnosis of Mycobacterium tuberculosis infection against a gradient of exposure in The Gambia. Clin Infect Dis. 2004 Apr 1;38(7):966-73. Epub 2004 Mar 16.

Starting date: October 2004
Ending date: December 2007
Last updated: October 4, 2007